{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:14:46Z","timestamp":1785233686785,"version":"3.55.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,1,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Vancomycin is the first-line agent to treat pulmonary infections caused by methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    (MRSA) in people with cystic fibrosis (PwCF). However, there is no consensus on vancomycin initial dosing in this population among health institutions, and there is a large variability in initial dosing across the United States. In this study, we characterized the pharmacokinetics (PK) of vancomycin in PwCF using a population PK approach. The clinical PK data to develop the population PK model were obtained from vancomycin therapeutic monitoring data from PwCF undergoing treatment for infections due to MRSA. The population PK model was then used to perform comprehensive Monte Carlo simulations to evaluate the probability of target attainment (PTA) of 12 different initial dosing scenarios. The area under the curve to minimum inhibitory concentration (MIC) ratio \u2265400 mg*h\/L and &lt;650 mg*h\/L were used as efficacy and toxicity targets for PTA analysis. A total of 181 vancomycin plasma concentrations were included in the analysis. A one-compartment model with first-order elimination best described the data. Weight significantly influenced the vancomycin PK (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). In the final model, clearance was estimated as 5.52 L\/h\/70 kg, and the volume of distribution was 31.5 L\/70 kg. The PTA analysis showed that at MIC = 1 \u00b5g\/mL, doses 1,500 q8h and 2,000 q12h showed the highest %PTA in achieving both efficacy and toxicity targets. The PTA results from this study may potentially inform the initial dosing regimens of vancomycin to treat pulmonary infections due to MRSA in PwCF.\n                  <\/jats:p>","DOI":"10.1128\/aac.00992-23","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T09:01:38Z","timestamp":1701939698000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-9054","authenticated-orcid":false,"given":"Venkata K.","family":"Yellepeddi","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah , Salt Lake City, Utah, USA"},{"name":"Department of Molecular Pharmaceutics, College of Pharmacy, University of Utah , Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Lindley","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy, University of North Texas Health Science Center , Fort Worth, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Radetich","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Center, University of Utah Health , Salt Lake City, Utah, USA"},{"name":"Department of Pharmacotherapy, College of Pharmacy, University of Utah , Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Kumar","sequence":"additional","affiliation":[{"name":"Parexel International , Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubin","family":"Bhakta","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Center, University of Utah Health , Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Leclair","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Center, University of Utah Health , Salt Lake City, Utah, USA"},{"name":"Department of Internal Medicine and Pulmonary Division, Spencer Fox Eccles School of Medicine, University of Utah , Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Parrot","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah , Salt Lake City, Utah, USA"},{"name":"Department of Molecular Pharmaceutics, College of Pharmacy, University of Utah , Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0977-7257","authenticated-orcid":false,"given":"David C.","family":"Young","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Center, University of Utah Health , Salt Lake City, Utah, USA"},{"name":"Department of Pharmacotherapy, College of Pharmacy, University of Utah , Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00849"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201402-050AS"},{"key":"e_1_3_3_4_2","unstructured":"Anonymous . Cystic fibrosis foundation patient registry 2021 annual data report. Available from: https:\/\/www.cff.org\/medical-professionals\/patient-registry. Retrieved 1010 MayMay 2023. Accessed 1010 MayMay 2023"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1836157"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.791"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23132"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-22.6.406"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/491712"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611040-00001"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.74"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.04.001"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0891-5520(03)00065-5"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz051"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.1.186"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26077"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_3_20_2","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known","volume":"5","author":"Du Bois D","year":"1989","unstructured":"Du Bois D , Du Bois EF . 1989. A formula to estimate the approximate surface area if height and weight be known. Nutrition 5:303\u2013311;","journal-title":"Nutrition"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_3_3_22_2","unstructured":"Mohamed Ismail SVW Mager DE . n.d. Finch studio: a next generation NONMEM modeling workbench. Available from: https:\/\/www.page-meeting.org\/default.asp?abstract=10062"},{"key":"e_1_3_3_23_2","unstructured":"Anonymous. R Core Team . 2021. R: a language and environment for statistical computing. R Foundation for Statistical Computing Vienna Austria. Available from: https:\/\/www.R-project.org"},{"key":"e_1_3_3_24_2","volume-title":"Rstudio, PBC","author":"Anonymous; RStudio Team","year":"2020","unstructured":"Anonymous; RStudio Team . 2020. Rstudio: Integrated development for R, . In Rstudio, PBC. , Boston, MA. http:\/\/www.rstudio.com."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1016215116835"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D374"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6749"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00241-23"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1093171"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001065"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1320"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.128260.1"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0250-x"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S11181"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051062"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00992-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00992-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T19:39:02Z","timestamp":1715801942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00992-23"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,10]]}},"alternative-id":["10.1128\/aac.00992-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.00992-23","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.07.28.551040","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"2023-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00992-23"}}